In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Boston Scientific’s current price at $45.13 is significantly below the PERT-weighted fair value of $75.00, indicating substantial implied upside of 66.2%. Monte Carlo analysis shows a wide value range with high volatility (104.14% coefficient of variation) and a downside risk of 20.6%, highlighting notable investment risk alongside growth potential. Overall financial health is good but growth scores are relatively low, suggesting moderate future expansion capacity.